ניטרודרם  5 TTS ישראל - עברית - Ministry of Health

ניטרודרם 5 tts

novartis israel ltd - glyceryl trinitrate - מדבקות - glyceryl trinitrate 25 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

ניטרודרם TTS 5 ישראל - עברית - Ministry of Health

ניטרודרם tts 5

novartis israel ltd - glyceryl trinitrate - מדבקות - glyceryl trinitrate 25 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

ניטרודרם 10 TTS ישראל - עברית - Ministry of Health

ניטרודרם 10 tts

novartis israel ltd - glyceryl trinitrate - מדבקות - glyceryl trinitrate 50 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

ניטרודרם TTS 10 ישראל - עברית - Ministry of Health

ניטרודרם tts 10

novartis israel ltd - glyceryl trinitrate - מדבקות - glyceryl trinitrate 50 mg/patch - glyceryl trinitrate - glyceryl trinitrate - prophylaxis of angina pectoris.

לופרסור דיויטבס 200 מג ישראל - עברית - Ministry of Health

לופרסור דיויטבס 200 מג

novartis israel ltd - metoprolol tartrate - טבליות בשחרור איטי - metoprolol tartrate 200 mg - metoprolol - metoprolol - hypertension, angina pectoris, arrhythmia, prophylaxis of migrain, prophylaxis of reinfarction.

קו-דיובאן 8012.5 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 8012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

קו-דיובאן 16012.5 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 16012.5 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

קו-דיובאן 16025 מג טבליות מצופות ישראל - עברית - Ministry of Health

קו-דיובאן 16025 מג טבליות מצופות

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

סנדוסטטין   0.1 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.1 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין   0.05 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.05 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.